Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
Brief Summary
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given together with the best pain management in treating neuropathic pain in patients with cancer.
PURPOSE: This randomized phase III trial is studying ketamine hydrochloride given together with the best pain management to see how well it works compared with giving a placebo together with the best pain management in treating cancer patients with neuropathic pain.
Intervention / Treatment
-
Ketamine Hydrochloride (DRUG)N/A
-
pharmacogenomic studies (OTHER)N/A
-
questionnaire administration (OTHER)N/A
-
assessment of therapy complications (PROCEDURE)N/A
-
quality-of-life assessment (PROCEDURE)N/A
Condition or Disease
- Cancer
Phase
Study Design
| Study type: | INTERVENTIONAL |
|---|---|
| Status: | Unknown status |
| Study results: | No Results Available |
| Age: | 18 Years and older (Adult, Older Adult) |
| Enrollment: | 214 (ESTIMATED) |
| Funded by: | Other |
| Allocation: | Randomized |
| Primary Purpose: | Supportive Care |
Masking |
|
Clinical Trial Dates
| Start date: | Apr 01, 2009 | |
|---|---|---|
| Primary Completion: | Oct 01, 2011 | ESTIMATED |
| Completion Date: | Aug 31, 2020 | |
| Study First Posted: | Mar 16, 2011 | ESTIMATED |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | May 12, 2011 |
Sponsors / Collaborators
Location
OBJECTIVES:
Primary
* To determine whether ketamine hydrochloride given in addition to best standard pain management improves malignant neuropathic pain compared to best standard pain management alone in patients with cancer.
Secondary
* To compare initial treatment benefit (at day 4 of assessment period of 16 days) using the sensory component of the McGill Short-Form Questionnaire.
* To compare difference in overall pain between the study arms based on the pain-intensity visual-analogue score (VAS).
* To compare difference in neuropathic pain between the study arms based on the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
* To assess worst pain score (index neuropathic site) between the two arms.
* To compare patient distress between the two arms based on NCCN Distress Thermometer.
* To assess the side effects and tolerability of trial drug.
* To assess the effect of intervention on quality of life scores (based on Euroqol thermometer), anxiety and depression (based on HADS), and opioid requirements.
OUTLINE: This is a multicenter study.
* Stage 1 (Run-in Period): Opioid doses are optimized, under a defined schedule, for up to a maximum of 10 days to ensure that all patients are on an optimized and stable regimen\* prior to randomization. Following the run-in-period, patients undergo reassessment. Patients who have improved pain scores (i.e., \< 4/10 on the visual-analogue score in the past 24 hours or \< 5 McGill Sensory Scale Score) are taken off the study. Patients whose scores have not improved continue on to Stage 2 of the study.
NOTE: \*Stable regimen is defined as the same dose of controlled release and no more variation than 2 breakthrough opioid doses over the normal for that patient for a period of 48 hours.
* Stage 2 (Titration Period): Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive oral ketamine hydrochloride 4 times a day. Doses are titrated until when analgesia is achieved or individual side effects appear, for up to 14 days.
* Arm II: Patients receive an oral placebo 4 times a day. Doses are titrated until when analgesia is achieved or individual side effects appear, for up to 14 days.
* Stage 3 (Assessment Period): Patients receive the trial medication (i.e., ketamine hydrochloride or placebo) at the fixed optimum dose (reached during the titration period) for 16 days.
Patients are allowed to receive breakthrough opioids at any time during the study.
Patients complete quality-of-life and pain-assessment questionnaires periodically. Some patients may undergo blood sample collection periodically for pharmacogenomics studies at a later date.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Primary
* To determine whether ketamine hydrochloride given in addition to best standard pain management improves malignant neuropathic pain compared to best standard pain management alone in patients with cancer.
Secondary
* To compare initial treatment benefit (at day 4 of assessment period of 16 days) using the sensory component of the McGill Short-Form Questionnaire.
* To compare difference in overall pain between the study arms based on the pain-intensity visual-analogue score (VAS).
* To compare difference in neuropathic pain between the study arms based on the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
* To assess worst pain score (index neuropathic site) between the two arms.
* To compare patient distress between the two arms based on NCCN Distress Thermometer.
* To assess the side effects and tolerability of trial drug.
* To assess the effect of intervention on quality of life scores (based on Euroqol thermometer), anxiety and depression (based on HADS), and opioid requirements.
OUTLINE: This is a multicenter study.
* Stage 1 (Run-in Period): Opioid doses are optimized, under a defined schedule, for up to a maximum of 10 days to ensure that all patients are on an optimized and stable regimen\* prior to randomization. Following the run-in-period, patients undergo reassessment. Patients who have improved pain scores (i.e., \< 4/10 on the visual-analogue score in the past 24 hours or \< 5 McGill Sensory Scale Score) are taken off the study. Patients whose scores have not improved continue on to Stage 2 of the study.
NOTE: \*Stable regimen is defined as the same dose of controlled release and no more variation than 2 breakthrough opioid doses over the normal for that patient for a period of 48 hours.
* Stage 2 (Titration Period): Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive oral ketamine hydrochloride 4 times a day. Doses are titrated until when analgesia is achieved or individual side effects appear, for up to 14 days.
* Arm II: Patients receive an oral placebo 4 times a day. Doses are titrated until when analgesia is achieved or individual side effects appear, for up to 14 days.
* Stage 3 (Assessment Period): Patients receive the trial medication (i.e., ketamine hydrochloride or placebo) at the fixed optimum dose (reached during the titration period) for 16 days.
Patients are allowed to receive breakthrough opioids at any time during the study.
Patients complete quality-of-life and pain-assessment questionnaires periodically. Some patients may undergo blood sample collection periodically for pharmacogenomics studies at a later date.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Age Groups: | Adult / Older Adult |
| Healthy Volunteers: | Yes |
DISEASE CHARACTERISTICS:
* Histologically confirmed cancer
* Index neuropathic pain ≥ 4 on 0-10 (as defined by Leeds Assessment of Neuropathic Symptoms and Signs) that is related to underlying malignancy or resulting from treatment received for this malignancy
* McGill Sensory Scale Score \> 5
* Received a trial of an adjuvant analgesic (gabapentin or amitriptyline or both)
PATIENT CHARACTERISTICS:
* Life expectancy ≥ 2 months
* Fertile patients must use effective contraception
* Able to comply with study procedures
* Diastolic blood pressure ≤ 100 mm Hg at screening
* No seizures in past 2 years
* Not actively hallucinating
* No cerebrovascular disease (strokes)
* No psychotic disorders or cognitive impairment
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* At least 6 weeks since prior and no concurrent chemotherapy or radiotherapy that is likely to affect neuropathic pain
* No change in tumoricidal treatment during the period of the study that is likely to alter pain during the course of the study
* No concurrent class I antiarrhythmic drugs
* Histologically confirmed cancer
* Index neuropathic pain ≥ 4 on 0-10 (as defined by Leeds Assessment of Neuropathic Symptoms and Signs) that is related to underlying malignancy or resulting from treatment received for this malignancy
* McGill Sensory Scale Score \> 5
* Received a trial of an adjuvant analgesic (gabapentin or amitriptyline or both)
PATIENT CHARACTERISTICS:
* Life expectancy ≥ 2 months
* Fertile patients must use effective contraception
* Able to comply with study procedures
* Diastolic blood pressure ≤ 100 mm Hg at screening
* No seizures in past 2 years
* Not actively hallucinating
* No cerebrovascular disease (strokes)
* No psychotic disorders or cognitive impairment
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* At least 6 weeks since prior and no concurrent chemotherapy or radiotherapy that is likely to affect neuropathic pain
* No change in tumoricidal treatment during the period of the study that is likely to alter pain during the course of the study
* No concurrent class I antiarrhythmic drugs
Primary Outcomes
-
Time to treatment failure
Secondary Outcomes
-
Initial treatment benefit (at day 4 of assessment period of 16 days) using the sensory component of the McGill Short-Form Questionnaire
-
Difference in overall pain between the study arms based on the visual-analogue score
-
Difference in neuropathic pain between the study arms based on the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale
-
Worst pain score (index neuropathic site) in the previous 24 hours (between the two arms) at study baseline and then during study assessment period
-
Patient distress between the two arms based on NCCN Distress Thermometer
-
Side effects and tolerability of trial drug
-
Effect of the intervention on quality-of-life scores (based on Euroqol thermometer), anxiety and depression (based on HAD scale), and opioid requirements
More Details
| NCT Number: | NCT01316744 |
|---|---|
| Other IDs: | CDR0000696704 |
| Study URL: | https://clinicaltrials.gov/study/NCT01316744 |
Last updated: Sep 29, 2023